Company Analysis
Sign in

Scribe Therapeutics Inc. (SCTX)

Nasdaq: SCTX · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.8
◀ Past 5.9● Present 6.5▶ Future 5.0
8 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

6 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Scribe Therapeutics Inc.’s names, not what it holds today.

Patents granted
6
6 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 3 in 2024 and 2 in 2023
Applications published
30
5 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology6
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Scribe Therapeutics Inc. its own name
named as the applicant on its applications, in US
0 granted
29 published
Scribe Therapeutics Inc. its own name
US, as the owner printed on each patent
6 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 10, 202412,163,125Engineered class 2 type V CRISPR systemsBiotechnologyScribe Therapeutics Inc.
Sep 10, 202412,084,692Guide scaffoldsBiotechnologyScribe Therapeutics Inc.
May 7, 202411,976,277Particle delivery systemsBiotechnologyScribe Therapeutics Inc.
Mar 28, 202311,613,742Compositions and methods for the targeting of SOD1BiotechnologyScribe Therapeutics Inc.
Jan 24, 202311,560,555Engineered proteinsBiotechnologyScribe Therapeutics Inc.
Dec 27, 202211,535,835Compositions and methods for the targeting of rhodopsinBiotechnologyScribe Therapeutics Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 27, 20252025/0361525AAV VECTORS FOR GENE EDITINGBiotechnologyScribe Therapeutics Inc.
Oct 30, 20252025/0333767ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMSBiotechnologyScribe Therapeutics Inc.
May 1, 20252025/0136962CATALYTICALLY DEAD ENGINEERED PROTEINSBiotechnologyScribe Therapeutics Inc.
Feb 6, 20252025/0043262GENE EDITING PAIRSBiotechnologyScribe Therapeutics Inc.
Jan 9, 20252025/0011756METHODS OF EDITING WITH ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMSBiotechnologyScribe Therapeutics Inc.
Nov 28, 20242024/0392271ENGINEERED CASX REPRESSOR SYSTEMSBiotechnologyScribe Therapeutics Inc.
Nov 14, 20242024/0376462ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMSBiotechnologyScribe Therapeutics Inc.
Oct 31, 20242024/0360474SELF-INACTIVATING VECTORS FOR GENE EDITINGBiotechnologyScribe Therapeutics Inc.
Sep 19, 20242024/0309344COMPOSITIONS AND METHODS FOR THE TARGETING OF C9orf72BiotechnologyScribe Therapeutics Inc.
Aug 1, 20242024/0254466ENGINEERED CLASS 2, TYPE V REPRESSOR SYSTEMSBiotechnologyScribe Therapeutics Inc.
What it applied for, 2024 to 2025: Biotechnology 18.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton SCTX · research, not advice